<?xml version="1.0" encoding="UTF-8"?>
<p id="para300">If trials show that the repurposed therapies are effective, in principle, they could be available for people with covid-19 just weeks later, as long as they can be manufactured in adequate amounts, says Clifford Lane, deputy director for clinical research at NIAID. Novel treatments could requires months of testing before they are ready for humans. It is a lengthy process, but it also helps to ensure that the massive investment of time and resources to get drugs to patients will pay off in the end. “We need to focus on what will bring the greatest benefit to the largest number of patients,” says Lane.</p>
